APRE
Aprea Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.51
−1.90%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.53
From 52W high−63.12%
Volume20479.00
Market cap$6.36M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$0.53
From 52W high
−63.12%
Volume
20479.00
Market cap
$6.36M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
2.8x
P/E (TTM)
—
RSI (14)
40.1
MomentumView details →
1D Return
−1.90%
YTD Return
−40.75%
SummaryUpdated Jun 1, 2026
Aprea Therapeutics, Inc. (NASDAQ:APRE) is a clinical-stage biopharmaceutical company founded in 2002 and based in Boston, Massachusetts. The company went public in October 2019 and focuses on developing novel cancer therapeutics that target DNA damage response pathways. Aprea operates as a small biotechnology firm dedicated to advancing innovative treatments for patients with advanced solid tumors through its pipeline of experimental drugs currently in various stages of clinical development.
Similar companies
Latest newsMore news →
Aprea Therapeutics reported third-quarter 2026 financial results, including $37.8 million in cash and cash equivalents as of September 30, 2026, and said its cash runway is expected to extend into the first quarter of 2028.13h agoAprea Therapeutics announced that it will host a virtual panel discussion on WEE1 inhibition in precision oncology on October 20, 2026, at 11 a.m. ET.20d ago